NCT02942264: Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma |
|
|
| Completed | 2 | 53 | US | Zotiraciclib (TG02), TG02, Temozolomide (TMZ), Temodar | National Cancer Institute (NCI) | Brain Tumor, Astrocytoma, Astroglioma, Glioblastoma, Gliosarcoma | 08/20 | 08/20 | | |
